During the past 20 years InSight has developed a wide portfolio of Biosimilars manufacturing technologies and products.
Multiple “first generation” off-patent products were developed and commercialized by InSight over the years:
- Interferon alpha (2a)
- Interferon alpha (2b)
- Interferon beta-1a
- Interferon beta-1b
In addition, technologies for the manufacturing of several “second generation” Biosimilars have been commercialized:
Currently, different products are manufactured at our GMP facility and our pipeline includes post 2020, “third generation” products in development.